Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
Cagrilintide
AM833, CagriSema (in combination with semaglutide)
A synthetic analog of amylin, a peptide hormone co-secreted with insulin by pancreatic beta cells. FDA-approved as an adjunct to insulin therapy in type 1 and type 2 diabetes. Represents the amylin pathway that cagrilintide (investigational) also targets.
A long-acting amylin analog developed by Novo Nordisk. Amylin is a hormone co-secreted with insulin that regulates appetite and gastric emptying. Being developed both standalone and in combination with semaglutide (CagriSema) — a combination showing weight loss exceeding 22% in Phase 3 trials, potentially the next step beyond tirzepatide.
Mimics the effects of amylin: slows gastric emptying, suppresses postprandial glucagon secretion, and promotes satiety. These effects complement insulin therapy by reducing postprandial glucose spikes and caloric intake.
Activates amylin receptors (CALCR/RAMP) in the brain, particularly in the area postrema and hypothalamus, reducing appetite through a pathway distinct from GLP-1. The combination with semaglutide targets two separate appetite-regulating systems simultaneously, producing additive weight loss beyond either agent alone.
- Type 1 diabetes (adjunct to insulin)
- Type 2 diabetes (adjunct to insulin)
- Postprandial glucose control
- Modest weight loss
- Weight management (investigational)
- Type 2 diabetes (investigational)
- Metabolic syndrome
- Severe hypoglycemia (especially in type 1 diabetes — boxed warning)
- Nausea (common, usually transient)
- Headache
- Anorexia
- Requires careful insulin dose adjustment
- GI side effects (nausea, vomiting) — similar to GLP-1 class
- Still in Phase 3 trials — full safety profile not established
- Injection site reactions
- Long-term effects unknown
FDA-approved as Symlin (2005) for type 1 and type 2 diabetes as an adjunct to mealtime insulin. Requires insulin dose reduction to prevent hypoglycemia. Pen injector for self-administration.
Currently in Phase 3 trials as CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg). Phase 3 REDEFINE 1 trial showed ~22.7% weight loss at 68 weeks. Potential FDA submission 2026-2027. Represents the next generation beyond tirzepatide in the weight management pipeline.
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.